Last 12 months
Inside the activity.
1 purchase rows · 1 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 1 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 17, 2021 Filed Aug 19, 2021 19:04 UTC |
WILLIAMS FRANK JDirector · Executive Chairman
|
Exercise / conversionClass A Common Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $3.84 | $0.00 |
DisclosureSEC source: 0001628908-21-000122 · wf-form4_162941423754385.xml · derivative · entry 5 WILLIAMS FRANK J · CIK 0001204938 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 659,060 Underlying: Class A Common Stock · 10,000 shares Expires 2024-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2021. F5 · derivative.exercise_date: The Class A Common Stock Options exercised vested on December 1, 2014. Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 19:04 UTC |
WILLIAMS FRANK JDirector · Executive Chairman
|
SaleClass A Common Stock | 10,000 | $22.88 | $228,800.00 |
DisclosureSEC source: 0001628908-21-000122 · wf-form4_162941423754385.xml · nonDerivative · entry 3 WILLIAMS FRANK J · CIK 0001204938 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 617,809 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2021. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.625 to $23.130, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 19:04 UTC |
WILLIAMS FRANK JDirector · Executive Chairman
|
SaleClass A Common Stock | 10,000 | $22.88 | $228,800.00 |
DisclosureSEC source: 0001628908-21-000122 · wf-form4_162941423754385.xml · nonDerivative · entry 2 WILLIAMS FRANK J · CIK 0001204938 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 627,809 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2021. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.625 to $23.130, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 19:04 UTC |
WILLIAMS FRANK JDirector · Executive Chairman
|
Exercise / conversionClass A Common Stock | 10,000 | $3.84 | $38,400.00 |
DisclosureSEC source: 0001628908-21-000122 · wf-form4_162941423754385.xml · nonDerivative · entry 1 WILLIAMS FRANK J · CIK 0001204938 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 637,809 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2021. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| August 10, 2021 Filed Aug 11, 2021 21:13 UTC |
Weinberg JonathanGeneral Counsel
|
Exercise / conversionClass A Common Stock Option (right to buy) · Derivative | 8,254 | $0.00 Strike: $3.84 | $0.00 |
DisclosureSEC source: 0001628908-21-000120 · wf-form4_162871638831352.xml · derivative · entry 3 Weinberg Jonathan · CIK 0001642833 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 8,254 shares Expires 2024-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2021. F4 · derivative.exercise_date: The Class A Common Stock Options exercised vested on February 1, 2018. Read SEC document |
| August 10, 2021 Filed Aug 11, 2021 21:13 UTC |
Weinberg JonathanGeneral Counsel
|
SaleClass A Common Stock | 8,254 | $24.01 | $198,178.54 |
DisclosureSEC source: 0001628908-21-000120 · wf-form4_162871638831352.xml · nonDerivative · entry 2 Weinberg Jonathan · CIK 0001642833 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,775 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2021. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.00 to $24.04, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| August 10, 2021 Filed Aug 11, 2021 21:13 UTC |
Weinberg JonathanGeneral Counsel
|
Exercise / conversionClass A Common Stock | 8,254 | $3.84 | $31,695.36 |
DisclosureSEC source: 0001628908-21-000120 · wf-form4_162871638831352.xml · nonDerivative · entry 1 Weinberg Jonathan · CIK 0001642833 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,029 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2021. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| August 09, 2021 Filed Aug 10, 2021 20:46 UTC |
Weinberg JonathanGeneral Counsel
|
Exercise / conversionClass A Common Stock Option (right to buy) · Derivative | 15,277 | $0.00 Strike: $3.84 | $0.00 |
DisclosureSEC source: 0001628908-21-000118 · wf-form4_162862833425415.xml · derivative · entry 6 Weinberg Jonathan · CIK 0001642833 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,254 Underlying: Class A Common Stock · 15,277 shares Expires 2024-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2021. F5 · derivative.exercise_date: The Class A Common Stock Options exercised vested on February 1, 2018. Read SEC document |
| August 09, 2021 Filed Aug 10, 2021 20:46 UTC |
Weinberg JonathanGeneral Counsel
|
SaleClass A Common Stock | 15,277 | $24.05 | $367,411.85 |
DisclosureSEC source: 0001628908-21-000118 · wf-form4_162862833425415.xml · nonDerivative · entry 4 Weinberg Jonathan · CIK 0001642833 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,775 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2021. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.00 to $24.13, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| August 09, 2021 Filed Aug 10, 2021 20:46 UTC |
Weinberg JonathanGeneral Counsel
|
Exercise / conversionClass A Common Stock | 15,277 | $3.84 | $58,663.68 |
DisclosureSEC source: 0001628908-21-000118 · wf-form4_162862833425415.xml · nonDerivative · entry 3 Weinberg Jonathan · CIK 0001642833 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,052 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2021. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 20:46 UTC |
Weinberg JonathanGeneral Counsel
|
Exercise / conversionClass A Common Stock Option (right to buy) · Derivative | 1,900 | $0.00 Strike: $3.84 | $0.00 |
DisclosureSEC source: 0001628908-21-000118 · wf-form4_162862833425415.xml · derivative · entry 5 Weinberg Jonathan · CIK 0001642833 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,531 Underlying: Class A Common Stock · 1,900 shares Expires 2024-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2021. F5 · derivative.exercise_date: The Class A Common Stock Options exercised vested on February 1, 2018. Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 20:46 UTC |
Weinberg JonathanGeneral Counsel
|
SaleClass A Common Stock | 1,900 | $24.11 | $45,809.00 |
DisclosureSEC source: 0001628908-21-000118 · wf-form4_162862833425415.xml · nonDerivative · entry 2 Weinberg Jonathan · CIK 0001642833 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,775 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2021. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.005 to $24.150, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 20:46 UTC |
Weinberg JonathanGeneral Counsel
|
Exercise / conversionClass A Common Stock | 1,900 | $3.84 | $7,296.00 |
DisclosureSEC source: 0001628908-21-000118 · wf-form4_162862833425415.xml · nonDerivative · entry 1 Weinberg Jonathan · CIK 0001642833 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,675 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2021. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| August 03, 2021 Filed Aug 4, 2021 17:48 UTC |
WILLIAMS FRANK JDirector · Executive Chairman
|
Exercise / conversionClass A Common Stock Option (right to buy) · Derivative | 25,871 | $0.00 Strike: $3.84 | $0.00 |
DisclosureSEC source: 0001628908-21-000112 · wf-form4_162811366582920.xml · derivative · entry 9 WILLIAMS FRANK J · CIK 0001204938 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 669,060 Underlying: Class A Common Stock · 25,871 shares Expires 2024-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2021. F7 · derivative.exercise_date: The Class A Common Stock Options exercised vested on December 1, 2014. Read SEC document |
| August 03, 2021 Filed Aug 4, 2021 17:48 UTC |
WILLIAMS FRANK JDirector · Executive Chairman
|
SaleClass A Common Stock | 25,919 | $23.02 | $596,655.38 |
DisclosureSEC source: 0001628908-21-000112 · wf-form4_162811366582920.xml · nonDerivative · entry 6 WILLIAMS FRANK J · CIK 0001204938 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 627,809 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2021. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.99 to $23.14, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| August 03, 2021 Filed Aug 4, 2021 17:48 UTC |
WILLIAMS FRANK JDirector · Executive Chairman
|
SaleClass A Common Stock | 25,871 | $23.02 | $595,550.42 |
DisclosureSEC source: 0001628908-21-000112 · wf-form4_162811366582920.xml · nonDerivative · entry 5 WILLIAMS FRANK J · CIK 0001204938 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 653,728 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2021. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.99 to $23.13, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| August 03, 2021 Filed Aug 4, 2021 17:48 UTC |
WILLIAMS FRANK JDirector · Executive Chairman
|
Exercise / conversionClass A Common Stock | 25,871 | $3.84 | $99,344.64 |
DisclosureSEC source: 0001628908-21-000112 · wf-form4_162811366582920.xml · nonDerivative · entry 4 WILLIAMS FRANK J · CIK 0001204938 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 679,599 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2021. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| August 03, 2021 Filed Aug 4, 2021 21:52 UTC |
Tutewohl SteveChief Operating Officer
|
Exercise / conversionClass A Common Stock Option (right to buy) · Derivative | 11,229 | $0.00 Strike: $18.25 | $0.00 |
DisclosureSEC source: 0001628908-21-000114 · wf-form4_162811393147458.xml · derivative · entry 12 Tutewohl Steve · CIK 0001811845 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 11,229 shares Expires 2027-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 3, 2021. F9 · derivative.exercise_date: The Class A Common Stock Options exercised vested on February 1, 2019, February 1, 2020 and February 1, 2021. Read SEC document |
| August 03, 2021 Filed Aug 4, 2021 21:52 UTC |
Tutewohl SteveChief Operating Officer
|
Exercise / conversionClass A Common Stock Option (right to buy) · Derivative | 13,801 | $0.00 Strike: $13.95 | $0.00 |
DisclosureSEC source: 0001628908-21-000114 · wf-form4_162811393147458.xml · derivative · entry 11 Tutewohl Steve · CIK 0001811845 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,313 Underlying: Class A Common Stock · 13,801 shares Expires 2028-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 3, 2021. F9 · derivative.exercise_date: The Class A Common Stock Options exercised vested on February 1, 2019, February 1, 2020 and February 1, 2021. Read SEC document |
| August 03, 2021 Filed Aug 4, 2021 21:52 UTC |
Tutewohl SteveChief Operating Officer
|
SaleClass A Common Stock | 13,801 | $23.02 | $317,699.02 |
DisclosureSEC source: 0001628908-21-000114 · wf-form4_162811393147458.xml · nonDerivative · entry 8 Tutewohl Steve · CIK 0001811845 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,103 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 3, 2021. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.00 to $23.14, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| August 03, 2021 Filed Aug 4, 2021 21:52 UTC |
Tutewohl SteveChief Operating Officer
|
Exercise / conversionClass A Common Stock | 13,801 | $13.95 | $192,523.95 |
DisclosureSEC source: 0001628908-21-000114 · wf-form4_162811393147458.xml · nonDerivative · entry 7 Tutewohl Steve · CIK 0001811845 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,904 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 3, 2021. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| August 03, 2021 Filed Aug 4, 2021 21:52 UTC |
Tutewohl SteveChief Operating Officer
|
SaleClass A Common Stock | 11,229 | $23.02 | $258,491.58 |
DisclosureSEC source: 0001628908-21-000114 · wf-form4_162811393147458.xml · nonDerivative · entry 6 Tutewohl Steve · CIK 0001811845 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,103 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 3, 2021. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $ 22.99 to $23.14, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| August 03, 2021 Filed Aug 4, 2021 21:52 UTC |
Tutewohl SteveChief Operating Officer
|
Exercise / conversionClass A Common Stock | 11,229 | $18.25 | $204,929.25 |
DisclosureSEC source: 0001628908-21-000114 · wf-form4_162811393147458.xml · nonDerivative · entry 5 Tutewohl Steve · CIK 0001811845 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,332 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 3, 2021. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 17:48 UTC |
WILLIAMS FRANK JDirector · Executive Chairman
|
Exercise / conversionClass A Common Stock Option (right to buy) · Derivative | 6,144 | $0.00 Strike: $3.84 | $0.00 |
DisclosureSEC source: 0001628908-21-000112 · wf-form4_162811366582920.xml · derivative · entry 8 WILLIAMS FRANK J · CIK 0001204938 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 694,931 Underlying: Class A Common Stock · 6,144 shares Expires 2024-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2021. F7 · derivative.exercise_date: The Class A Common Stock Options exercised vested on December 1, 2014. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 17:48 UTC |
WILLIAMS FRANK JDirector · Executive Chairman
|
SaleClass A Common Stock | 6,165 | $23.02 | $141,918.30 |
DisclosureSEC source: 0001628908-21-000112 · wf-form4_162811366582920.xml · nonDerivative · entry 3 WILLIAMS FRANK J · CIK 0001204938 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 653,728 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2021. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.00 to $23.13, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 17:48 UTC |
WILLIAMS FRANK JDirector · Executive Chairman
|
SaleClass A Common Stock | 6,144 | $23.02 | $141,434.88 |
DisclosureSEC source: 0001628908-21-000112 · wf-form4_162811366582920.xml · nonDerivative · entry 2 WILLIAMS FRANK J · CIK 0001204938 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 659,893 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2021. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.00 to $23.13, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 17:48 UTC |
WILLIAMS FRANK JDirector · Executive Chairman
|
Exercise / conversionClass A Common Stock | 6,144 | $3.84 | $23,592.96 |
DisclosureSEC source: 0001628908-21-000112 · wf-form4_162811366582920.xml · nonDerivative · entry 1 WILLIAMS FRANK J · CIK 0001204938 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 666,037 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2021. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 21:52 UTC |
Tutewohl SteveChief Operating Officer
|
Exercise / conversionClass A Common Stock Option (right to buy) · Derivative | 2,625 | $0.00 Strike: $18.25 | $0.00 |
DisclosureSEC source: 0001628908-21-000114 · wf-form4_162811393147458.xml · derivative · entry 10 Tutewohl Steve · CIK 0001811845 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,229 Underlying: Class A Common Stock · 2,625 shares Expires 2027-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 3, 2021. F8 · derivative.exercise_date: The Class A Common Stock Options exercised vested on February 1, 2018 and February 1, 2019. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 21:52 UTC |
Tutewohl SteveChief Operating Officer
|
Exercise / conversionClass A Common Stock Option (right to buy) · Derivative | 3,331 | $0.00 Strike: $13.95 | $0.00 |
DisclosureSEC source: 0001628908-21-000114 · wf-form4_162811393147458.xml · derivative · entry 9 Tutewohl Steve · CIK 0001811845 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,114 Underlying: Class A Common Stock · 3,331 shares Expires 2028-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 3, 2021. F7 · derivative.exercise_date: The Class A Common Stock Options exercised vested on February 1, 2019. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 21:52 UTC |
Tutewohl SteveChief Operating Officer
|
SaleClass A Common Stock | 2,625 | $23.02 | $60,427.50 |
DisclosureSEC source: 0001628908-21-000114 · wf-form4_162811393147458.xml · nonDerivative · entry 4 Tutewohl Steve · CIK 0001811845 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,103 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 3, 2021. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.99 to $23.13, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 21:52 UTC |
Tutewohl SteveChief Operating Officer
|
Exercise / conversionClass A Common Stock | 2,625 | $18.25 | $47,906.25 |
DisclosureSEC source: 0001628908-21-000114 · wf-form4_162811393147458.xml · nonDerivative · entry 3 Tutewohl Steve · CIK 0001811845 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,728 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 3, 2021. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 21:52 UTC |
Tutewohl SteveChief Operating Officer
|
SaleClass A Common Stock | 3,331 | $23.02 | $76,679.62 |
DisclosureSEC source: 0001628908-21-000114 · wf-form4_162811393147458.xml · nonDerivative · entry 2 Tutewohl Steve · CIK 0001811845 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,103 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 3, 2021. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.00 to $23.13, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 21:52 UTC |
Tutewohl SteveChief Operating Officer
|
Exercise / conversionClass A Common Stock | 3,331 | $13.95 | $46,467.45 |
DisclosureSEC source: 0001628908-21-000114 · wf-form4_162811393147458.xml · nonDerivative · entry 1 Tutewohl Steve · CIK 0001811845 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,434 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 3, 2021. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| July 30, 2021 Filed Aug 3, 2021 18:57 UTC |
WILLIAMS FRANK JDirector · Executive Chairman
|
Exercise / conversionClass A Common Stock Option (right to buy) · Derivative | 1,901 | $0.00 Strike: $3.84 | $0.00 |
DisclosureSEC source: 0001628908-21-000105 · wf-form4_162803142242679.xml · derivative · entry 5 WILLIAMS FRANK J · CIK 0001204938 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 701,075 Underlying: Class A Common Stock · 1,901 shares Expires 2024-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2021. F4 · derivative.exercise_date: The Class A Common Stock Options exercised vested on December 1, 2014. Read SEC document |
| July 30, 2021 Filed Aug 3, 2021 18:57 UTC |
WILLIAMS FRANK JDirector · Executive Chairman
|
SaleClass A Common Stock | 1,601 | $23.00 | $36,823.00 |
DisclosureSEC source: 0001628908-21-000105 · wf-form4_162803142242679.xml · nonDerivative · entry 3 WILLIAMS FRANK J · CIK 0001204938 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 659,893 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2021. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| July 30, 2021 Filed Aug 3, 2021 18:57 UTC |
WILLIAMS FRANK JDirector · Executive Chairman
|
SaleClass A Common Stock | 1,901 | $23.00 | $43,723.00 |
DisclosureSEC source: 0001628908-21-000105 · wf-form4_162803142242679.xml · nonDerivative · entry 2 WILLIAMS FRANK J · CIK 0001204938 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 661,494 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2021. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| July 30, 2021 Filed Aug 3, 2021 18:57 UTC |
WILLIAMS FRANK JDirector · Executive Chairman
|
Exercise / conversionClass A Common Stock | 1,901 | $3.84 | $7,299.84 |
DisclosureSEC source: 0001628908-21-000105 · wf-form4_162803142242679.xml · nonDerivative · entry 1 WILLIAMS FRANK J · CIK 0001204938 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 663,395 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2021. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| July 19, 2021 Filed Jul 21, 2021 17:23 UTC |
WILLIAMS FRANK JDirector · Executive Chairman
|
Exercise / conversionClass A Common Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $3.84 | $0.00 |
DisclosureSEC source: 0001628908-21-000102 · wf-form4_162690259202984.xml · derivative · entry 5 WILLIAMS FRANK J · CIK 0001204938 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 702,976 Underlying: Class A Common Stock · 10,000 shares Expires 2024-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2021. F5 · derivative.exercise_date: The Class A Common Stock Options exercised vested on December 1, 2014. Read SEC document |
| July 19, 2021 Filed Jul 21, 2021 17:23 UTC |
WILLIAMS FRANK JDirector · Executive Chairman
|
SaleClass A Common Stock | 10,000 | $21.60 | $216,000.00 |
DisclosureSEC source: 0001628908-21-000102 · wf-form4_162690259202984.xml · nonDerivative · entry 3 WILLIAMS FRANK J · CIK 0001204938 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 661,494 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2021. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.26 to $22.00, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| July 19, 2021 Filed Jul 21, 2021 17:23 UTC |
WILLIAMS FRANK JDirector · Executive Chairman
|
SaleClass A Common Stock | 10,000 | $21.60 | $216,000.00 |
DisclosureSEC source: 0001628908-21-000102 · wf-form4_162690259202984.xml · nonDerivative · entry 2 WILLIAMS FRANK J · CIK 0001204938 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 671,494 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2021. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.26 to $22.00, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| July 19, 2021 Filed Jul 21, 2021 17:23 UTC |
WILLIAMS FRANK JDirector · Executive Chairman
|
Exercise / conversionClass A Common Stock | 10,000 | $3.84 | $38,400.00 |
DisclosureSEC source: 0001628908-21-000102 · wf-form4_162690259202984.xml · nonDerivative · entry 1 WILLIAMS FRANK J · CIK 0001204938 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 681,494 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2021. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| July 09, 2021 Filed Jul 13, 2021 21:27 UTC |
WILLIAMS FRANK JDirector · Executive Chairman
|
Exercise / conversionClass A Common Stock Option (right to buy) · Derivative | 3,584 | $0.00 Strike: $3.84 | $0.00 |
DisclosureSEC source: 0001628908-21-000100 · wf-form4_162622602008289.xml · derivative · entry 5 WILLIAMS FRANK J · CIK 0001204938 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 712,976 Underlying: Class A Common Stock · 3,584 shares Expires 2024-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2021. F4 · derivative.exercise_date: The Class A Common Stock Options exercised vested on December 1, 2014. Read SEC document |
| July 09, 2021 Filed Jul 13, 2021 21:27 UTC |
WILLIAMS FRANK JDirector · Executive Chairman
|
SaleClass A Common Stock | 3,584 | $23.00 | $82,432.00 |
DisclosureSEC source: 0001628908-21-000100 · wf-form4_162622602008289.xml · nonDerivative · entry 3 WILLIAMS FRANK J · CIK 0001204938 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 671,494 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2021. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| July 09, 2021 Filed Jul 13, 2021 21:27 UTC |
WILLIAMS FRANK JDirector · Executive Chairman
|
Exercise / conversionClass A Common Stock | 3,584 | $3.84 | $13,762.56 |
DisclosureSEC source: 0001628908-21-000100 · wf-form4_162622602008289.xml · nonDerivative · entry 2 WILLIAMS FRANK J · CIK 0001204938 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 675,078 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2021. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| July 09, 2021 Filed Jul 13, 2021 21:27 UTC |
WILLIAMS FRANK JDirector · Executive Chairman
|
SaleClass A Common Stock | 3,584 | $23.00 | $82,432.00 |
DisclosureSEC source: 0001628908-21-000100 · wf-form4_162622602008289.xml · nonDerivative · entry 1 WILLIAMS FRANK J · CIK 0001204938 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 671,494 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2021. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| July 09, 2021 Filed Jul 14, 2021 01:22 UTC |
Tutewohl SteveChief Operating Officer
|
Exercise / conversionClass A Common Stock Option (right to buy) · Derivative | 1,465 | $0.00 Strike: $18.25 | $0.00 |
DisclosureSEC source: 0001628908-21-000098 · wf-form4_162622569628328.xml · derivative · entry 9 Tutewohl Steve · CIK 0001811845 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,854 Underlying: Class A Common Stock · 1,465 shares Expires 2027-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 3, 2021. F6 · derivative.exercise_date: The Class A Common Stock Options exercised vested on February 1, 2018. Read SEC document |
| July 09, 2021 Filed Jul 14, 2021 01:22 UTC |
Tutewohl SteveChief Operating Officer
|
Exercise / conversionClass A Common Stock Option (right to buy) · Derivative | 1,808 | $0.00 Strike: $13.95 | $0.00 |
DisclosureSEC source: 0001628908-21-000098 · wf-form4_162622569628328.xml · derivative · entry 8 Tutewohl Steve · CIK 0001811845 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,445 Underlying: Class A Common Stock · 1,808 shares Expires 2028-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 3, 2021. F5 · derivative.exercise_date: The Class A Common Stock Options exercised vested on February 1, 2019. Read SEC document |
| July 09, 2021 Filed Jul 14, 2021 01:22 UTC |
Tutewohl SteveChief Operating Officer
|
Exercise / conversionClass A Common Stock Option (right to buy) · Derivative | 10,576 | $0.00 Strike: $13.29 | $0.00 |
DisclosureSEC source: 0001628908-21-000098 · wf-form4_162622569628328.xml · derivative · entry 7 Tutewohl Steve · CIK 0001811845 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,776 Underlying: Class A Common Stock · 10,576 shares Expires 2029-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 3, 2021. F4 · derivative.exercise_date: The Class A Common Stock Options exercised vested on March 1, 2020 and March 1, 2021. Read SEC document |
| July 09, 2021 Filed Jul 14, 2021 01:22 UTC |
Tutewohl SteveChief Operating Officer
|
SaleClass A Common Stock | 1,465 | $23.00 | $33,695.00 |
DisclosureSEC source: 0001628908-21-000098 · wf-form4_162622569628328.xml · nonDerivative · entry 6 Tutewohl Steve · CIK 0001811845 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,103 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 3, 2021. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| July 09, 2021 Filed Jul 14, 2021 01:22 UTC |
Tutewohl SteveChief Operating Officer
|
Exercise / conversionClass A Common Stock | 1,465 | $18.25 | $26,736.25 |
DisclosureSEC source: 0001628908-21-000098 · wf-form4_162622569628328.xml · nonDerivative · entry 5 Tutewohl Steve · CIK 0001811845 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,568 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 3, 2021. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.